Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.43

+1.60 (4.87%)

as of Jun 4, 2026, 8:00:00 pm Market Open.

69 watching

Investor Insights

Jun 4, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Teva Pharmaceutical, traded under the symbol TEVA-N, has shown significant improvement, gaining 264% since the new CEO took office in January 2023, suggesting a robust turnaround for the company. After experiencing a rough period post-2002, recent positive financial results indicate that the company's performance is on the upswing. The headquarters in Israel underline its position as a large-cap player in the pharmaceutical industry. Under the current market conditions, Teva is ranked #1 in its ADR/CDR universe, benefiting from a rotation towards drug stocks. Its stock broke through the $21 barrier in September, continuing its upward trend with strong accumulation for the past six months, despite not currently offering a dividend. Analysts are optimistic about its prospects, projecting a price target of $34.50.

Consensus

Positive

Valuation

Undervalued

Similar

Pfeizer, PFE

BUY ON WEAKNESS

Likes generics. Feels you will get a much lower entry point for the stock because the company has a branded drug Copaxone for MS, which is constantly scrutinized by the Street and they have very low expectations of it. Strategy had really lacked. Street is now getting comfortable with the new strategy where they are focusing on non-North American generics, which is really where the market is growing and they are moving away from the branded portfolios.

TOP PICK

Earnings growth has been disappointing over the past couple of years but right now it is trading at 7X earnings and he thinks it is going to earn over $5 a share. Just recently boosted its dividend so now has a dividend over 3%. Strong pipeline and a sizable exposure to many blockbuster drugs.

SELL

(Market Call Minute) Biggest product is an MS drug with lots of competition.

COMMENT

Generic as well as some branded drugs. This is probably what has been hurting the stock to a certain extent in that their most valuable drug will expire in 2015 and this represents 50% of their margins. Long-term, great but lots of competition.

PAST TOP PICK

(Top Pick Jan 16/12, Down 12.39%)

DON'T BUY

Generics space. He would look to something like a Watson (WPI-N).

BUY

New CEO, disappointing earnings, but market breathed a sigh of relief. Huge free cash flow. There is no reason why it should not be trading at the same multiple as other pharmas. It’s all about dividends. Lots of competition on generic side.

COMMENT

Doesn’t know particularly well. Generic business makes economic sense. Around the world there will be more desire to use generics. Not on his radar screen because metrics aren’t particularly compelling.

BUY

One of the largest manufacturers of generic drugs globally. Thought their last quarter was pretty strong. Not sure why the market doesn't like the stock better. With the Cdn$ around par, it is a good opportunity to Buy. Inexpensive.

COMMENT

(Market Call Minute.) Stock has been weak for some time because of concerns over its multiple sclerosis drug. Just got a patent extension for another couple of years. Generic prices keep coming down and squeezing prices.

TOP PICK

Big company. 60 Companies. 8.5 x earnings. Will have patented products of their own soon. Due for a big upside move.

DON'T BUY

He is not a bottom picker but prefers to find the strongest companies within an industry and focus on those leaders. A few years ago the generic manufacturers were taking market share dramatically and their share prices were doing very well. Now if you look at the pharmaceutical companies as a whole, the ethical drug companies look much better situated than the generics. (See Top Picks.)

PAST TOP PICK

(Top Pick Mar 1/11, Down 9.03%) The stock hasn’t worked out. He bought more at $40. Raised dividend 11 years in a row, made a nice acquisition. He does not know why it is at these levels.

TOP PICK

Likes companies that have low valuations, great history of rising dividends and potential for double digit earnings growth in the coming year. Thinks it will earn $5.50 in 2012. Trading at 8X earnings. Raised its dividends 12 years in a row. Thinks they will be very active looking to acquire big quality branded orphan drugs.

STRONG BUY

Not sure why it has been beaten up so much but may have to do with a recent acquisition and concerns on how they are going to integrate it. 3 of the worst performing stocks this year are financials, pharmaceuticals and technology. Very, very cheap valuation. Raised its dividends 10 years in a row.

Showing 136 to 150 of 274 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)